Increase of the number of votes in Hansa Biopharma
Lund, Sweden, June 30, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, announced today that the number of outstanding votes in Hansa have increased during the month of June 2022 as a result of the conversion of a total of 114,666 class C shares to a total of 114,666 ordinary shares.
The conversion was carried out by Hansa in order to deliver ordinary shares to participants in the company’s incentive program adopted at the annual general meeting in 2019. The total number of votes in Hansa has therefore increased while the total number of shares remain unchanged.
As of today, the total number of registered and outstanding shares of Hansa amounts to 46,335,361, whereof 44,588,118 are ordinary shares and 1,747,243 are class C shares. As of today, the number of votes in Hansa amounts to 44,762,842.3.
This information is information that Hansa Biopharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on June 30, 2022, at 17:35 CEST
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com
Katja Margell
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.